Shanghai Fosun Pharmaceutical (02196) released its performance for the first three quarters, with a net profit attributable to shareholders of 2.523 billion yuan, an increase of 25.5% year-on-year.

Shanghai Fosun Pharmaceutical (02196) released its performance for the nine months ending September 30, 2025. The group achieved operating income of RMB 29.393 billion, a decrease of 4.91% year-on-year; net profit attributable to shareholders of the listed company was RMB 2.523 billion, an increase of 25.5% year-on-year; and basic earnings per share were RMB 0.95. In the first three quarters of 2025 and the current reporting period (July-September), operating income decreased year-on-year, mainly due to the impact of the renewal of centralized procurement for drugs and the implementation of centralized procurement in some local areas, but income from innovative drugs showed steady growth during the same period. In the first three quarters of 2025, total profit, net profit attributable to shareholders of the listed company, and basic and diluted earnings per share increased year-on-year, mainly due to the contribution of income from the sale of the remaining equity of United Family Healthcare and other non-core assets.